CloudHospital Inc.’s Post

💊🩸 Oxaliplatin, a chemotherapy drug, can cause a rare but severe condition called immune thrombocytopenia, leading to dangerously low platelet counts.   📈 A 55-year-old patient with stage 4 pancreatic cancer developed this complication after his 18th cycle of chemotherapy. Despite initial treatments with steroids and platelet infusions, his condition persisted. However, plasmapheresis—combined with continued steroid therapy—gradually restored his platelet count.   🔓 https://lnkd.in/dRmJ6DTw   #internalmedicine #CaseReport #meded #FOAMed #ejcrim #chemotherapy #cancer #thrombocytopenia #plasmapheresis

Getting To Know Your Medications Capecitabine: A potent oral chemotherapy medication used in treating breast, colorectal, and gastric cancers by disrupting cancer cell growth. . . . . . . . . At Getmeds, we understand the importance of accessibility to essential medications. That's why we strive to offer capecitabine at a competitive price, ensuring that cost is not a barrier to effective cancer treatment. Trust Getmeds to provide quality medications at prices that make a difference in your fight against cancer. #cancer #onco #breastcancer #coloncancer #gastriccancer #medicine #treatment #pharma #capecitabine

#OBRxBrands #OurWorkWednesday KISQALI is indicated: – in combination with an aromatase inhibitor for the adjuvant treatment of adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative stage II and III early breast cancer (eBC) at high risk of recurrence  – for the treatment of adults with HR-positive, HER2-negative advanced or metastatic breast cancer (mBC) in combination with: – an aromatase inhibitor as initial endocrine-based therapy; or – fulvestrant as initial endocrine-based therapy or following disease progression on endocrine therapy To Learn More: https://lnkd.in/e7bbUqva #OptiBrand #OptiBrandRx #OBRx #OWW #Pharma #PharmaMarketResearch #PharmaStrategy #strategy #marketresearch #getmore #PharmaExperts 

Although fewer women are dying of ovarian cancer (a decrease of 40% since 1975), 3D Predict™ can help continue this trend by working with oncologists to ensure that women are getting the right treatment for their cancer type. Learn more: bit.ly/3DPPlatform #Kiyatec #3DPredict #CancerTreatment #Chemotherapy #PatientCare #OvarianCancer #OncologyInnovation

🚀Revolutionizing Prostate Cancer Theranostics!🚀 Discover groundbreaking advancements in prostate cancer theranostics, merging therapy and diagnostics to improve patient outcomes.🧬 This innovative approach is paving the way for precision medicine and enhanced cancer care.💊 Shuttle Pharmaceuticals, Inc. Mr. Peter Dritschilo, Mr. Michael Vander Hoek Know complete story - https://lnkd.in/dnQT_asf #ProstateCancer #Theranostics #PrecisionMedicine #CancerCare #PharmaInnovation

🚀 FDA Approval Alert! 🚀 FDA approved durvalumab (Imfinzi, AstraZeneca) for adults with limited-stage small cell lung cancer (LS-SCLC) whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy. This approval is based on the ADRIATIC trial, which demonstrated a significant improvement in overall survival (OS) and progression-free survival (PFS) for patients treated with durvalumab compared to placebo. This is a major advancement in the treatment of LS-SCLC. 🔗 Read more about the approval #FDAApproval #Imfinzi #CancerTreatment #Oncology #HealthcareInnovation #MedicalResearch #LungCancer #ClinicalTrials #PharmaNews #Safevig solutions sandeep laveti Sneha Akkangire .

New article in Drugs in Context Nivolumab plus ipilimumab with chemotherapy in metastatic NSCLC: minireview and a case study of a patient negative for PD-L1 Alessandro Morabito Clinical case of a patient who, despite testing negative for PD-L1, displayed a sustained complete response to immunotherapy treatment in advanced metastatic non-small-cell lung cancer along with a review of recent findings concerning the application of immunotherapy in this context. #drugsincontext #oncology #immunecheckpoints #nsclc #lungcancer #pdl1 #chemotherapy #pharmacology https://lnkd.in/eb2VmEJ6

💫 #ONCOnews 💫 🌟 Merck Announces Phase 3 Trial of Subcutaneous Pembrolizumab With Berahyaluronidase Alfa Met Primary Endpoints 👉 Investigational subcutaneous pembrolizumab and berahyaluronidase alfa, in combination with chemotherapy, demonstrates noninferior pharmacokinetics compared to intravenous KEYTRUDA in combination with chemotherapy in adults with metastatic non-small cell lung cancer 🔗 https://buff.ly/4fB8rwb #OncEd #OncoAlert

The FDA has approved Hercessi (trastuzumab-strf) intravenous injection as a biosimilar to Herceptin (trastuzumab) for the treatment of adjuvant breast cancer, metastatic breast cancer, and metastatic gastric cancer. Hercessi’s labeling includes a Boxed Warning regarding the risks of cardiomyopathy, infusion reactions, pulmonary toxicity, and embryo-fetal toxicity. For all the latest #drugnews, check out our drug referential resource: https://ow.ly/hnno50RqYGP #medication #pharmacy

Compared to one or the other, combining preoperative and postoperative chemotherapy may improve long-term survival for patients with esophageal cancer. https://lnkd.in/eaBb6bmJ #esophogealcancer #cancersurvival #chemotherapy